Slide 1: Oriola Corporation Interim report Q1 2021
Oriola Corporation Interim report Q1 2021
Slide 2: Q1 2021 key points
Q1 2021 key points ”Profit weakened due to the increased demand volatility of the amplified pandemic" • The third wave of the COVID-19 pandemic affected societies of Finland and Sweden significantly, Oriola’s markets declined. • Market declined by ~6%, invoicing and net sales declined by 6% in const
Slide 3: Key figures
Key figures continuing operations Invoicing Net sales Adjusted EBIT EUR million EUR million EUR million 4 000 3 765 2 000 50 3 733 3 518 1 801 3 500 3 336 1 721 1 528 1 552 40 39.0 3 000 1 500 34.4 2 500 30 2 000 1 000 20.5 21.0 20 1 500 1 000 500 10 500 797 848 894 965 942 367 388 397 460 450 10.8
Slide 4: Adjusted EBIT
Adjusted EBIT Adjusted EBIT Adjusted EBIT development1 EUR million EUR million 10 10 8 8 6 6 9.1 4 8.0 4 -6.0 6.9 6.3 6.9 5.6 2 2 2.1 0.3 0.8 -1.5 -0.3 0.1 0.3 0 0 2020 Consumer Retail Pharma Group 2021 2019 2019 2019 2020 2020 2020 2020 2021 Q1 items Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Oriola estimates that
Slide 5: Focus21: short-term initiative to simplify and prioritise 2021 activities
Focus21: short-term initiative to simplify and prioritise 2021 activities • Based on the significant COVID-19-driven impacts in the markets and their 1. Prioritise value temporary effects on Oriola, the company started Focus21 initiative. creation and defend Oriola’s full-year profit • Through Focus
Slide 6: Operating environment
& Oriola Operating environment
Slide 7: Consumer markets
Consumer markets Pharmacy market value and volume declined in Sweden in Q1 Pharmacy market value development in Sweden in Q1: -6.0% Online pharmacy market size in Sweden Market shares Pharmacy 397 market BSEK 3 2 1 0 49 BSEK 49 BSEK 2017 Q1 2017 Q2 2017 Q3 2017 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 201
Slide 8: Pharma markets
Pharma markets Pharmaceutical market value and volume declined in Q1 Pharmaceutical market value development in Q1: Finland -5.9% and Sweden -5.8% Finland Wholesale Sweden Wholesale 2.8 BEUR 48 BSEK Oriola 42% (43%) Oriola 46% (46%) Others 58% (57%) Others 54% (54%) Market shares are quarterly Sourc
Slide 9: Retail markets
Retail markets Market share dose dispensing TG/OTC products supply for pharmacies in Sweden Sweden Total 230,000 Oriola 43% (43%) Others 57% (57%) 25% (25%) patients from the total market of SEK 13 billion Market share is quarterly figure and market size rolling 12 month figure Finland Staffing serv
Slide 10: Business Area reviews Q1 2021
Business Area reviews Q1 2021
Slide 11: Three customer-centric business areas
Three customer-centric business areas Consumer business area Pharma business area Retail business area Pharmacy services and products for Advanced logistics, expert and advisory A wide range of health and wellbeing consumer health and wellbeing in Sweden services for pharmaceutical companies, produc
Slide 12: Consumer Q1: Steep, temporary changes in the pharmacy market affected profit significantly
Consumer Q1: Steep, temporary changes in the pharmacy market affected profit significantly • COVID-19 restrictions temporarily impacted consumer Adjusted EBIT behavior, significantly decreasing the demand for EUR million pharmaceuticals 6 • Net sales declined by 6.4% to 189.4 M€ in constant currency
Slide 13: Pharma Q1: Exceptionally high volume volatility affected performance
Pharma Q1: Exceptionally high volume volatility affected performance • Net sales decreased by 6.3% to 228.7 M€ in Adjusted EBIT constant currency EUR million • Pharmaceutical volumes still temporarily down 6 due to the pandemic, with very strong volatility. 5 • Adjusted EBIT decreased to 2.0 M€ due
Slide 14: Retail Q1: Progress in many areas amid temporarily declining market
Retail Q1: Progress in many areas amid temporarily declining market • Net sales decreased by 3.7% to Adjusted EBIT EUR million 116.8 M€ in constant currency • The demand for health and wellbeing 1.5 products was soft due to the COVID 19- 1.0 pandemic. 1.5 1.1 • Adjusted EBIT increased to 1.1 M€. Pos
Slide 15: Financial review Q1 2021
& Oriola Financial review Q1 2021
Slide 16: Invoicing and net sales
Invoicing and net sales Invoicing1 Net sales2 EUR million EUR million 1 000 500 800 400 600 300 942 979 965 987 942 460 466 917 898 915 448 429 447 436 439 450 400 200 979 200 100 0 0 2019 2019 2019 2020 2020 2020 2020 2021 2019 2019 2019 2020 2020 2020 2020 2021 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 17: Adjusted EBIT
Adjusted EBIT Adjusted EBIT1 Adjusted EBIT development1 EUR million EUR million 10 10 8 8 6 6 4 8.0 4 -6.0 6.9 6.3 6.9 2 2 0.8 0.3 -1.5 0.1 0.3 -0.3 0 0 2020 2020 2020 2020 2021 2020 Consumer Retail Pharma Group 2021 Q1 Q2 Q3 Q4 Q1 Q1 items Q1 1Q1/2021 adjusted EBIT at comparable EUR/SEK rate EUR 0.
Slide 18: Profit for the period and earnings per share
Profit for the period and earnings per share Profit for the period Earnings per share EUR million EUR 6 0.06 4 0.04 0.03 0.02 0.02 5.1 0.02 2 4.5 4.1 0.02 3.7 0.01 2.0 0 0.00 -0.2 0.00 -1.6 -1.7 -0.01 -0.01 -2 -0.02 2019 2019 2019 2020 2020 2020 2020 2021 2019 2019 2019 2020 2020 2020 2020 2021 Q2 Q
Slide 19: Cash flow
Cash flow Quarterly net cash flow from operating activities Q1 YTD 2021 change in cash EUR million EUR million 80 200 -14.2 60 -6.7 150 -11.5 40 70 20 46 100 27 168.2 13 9 0 4 135.7 0 -14 50 -20 -40 0 2019 2019 2019 2020 2020 2020 2020 2021 Cash Operating Investing Financing Cash Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 20: Net Interest-Bearing Debt
Net Interest-Bearing Debt Net interest-bearing debt Net interest-bearing debt items EUR million EUR million 200 Net interest-bearing debt item 31 Mar 2021 31 Mar 2020 Bank loans 116.3 56.3 150 (syndicated Bank & term) Commercial papers 73.5 88.9 Advance payment from pharmacies 16.8 15.4 100 Lease li
Slide 21: Key take-aways
Key take-aways Adverse temporary Pharmaceutical Online sales Simplified focus Focus Sweden impacts volumes growth faster than to reach strategic programme particularly in the declined in market and business to strengthen Swedish market due RX and OTC in Consumer performance businesses in to the ampl
Slide 22: Outlook for 2021 unchanged
Outlook for 2021 unchanged The adjusted EBIT on a constant currency basis stays on the same level or increases from the 2020 level. The COVID-19 pandemic is expected to continue during 2021. Severity and duration of the pandemic remain unclear in Oriola’s operating environment. Oriola’s business out
Slide 23: Thank you!
Thank you! Our next events: 20/7/2021 Half year financial report 1-6/2021 27/10/2021 Interim Report 1-9/2021 25/11/2021 Capital Markets Day IR contact: Katja Graff, Treasury & IR Manager, +358 10 429 013 or katja.graff@oriola.com